Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,554.52
(
-0.79%
)
US TECH 100
23,457.60
(
-1.11%
)
Dow Jones
45,780.49
(
-0.52%
)
Brent Oil
106.23
(
1.72%
)
Bitcoin
69,976.00
(
0.11%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: cash2go post# 17845

Sunday, 02/08/2009 6:50:16 PM

Sunday, February 08, 2009 6:50:16 PM

Post# of 19309
>Why no ATryn sales in Europe?<

I believe the answer is as stated in #msg-33917434:

Leo priced ATryn too high to compete effectively against the plasma-derived products in Europe. Leo did this to maintain the opportunity for premium pricing in the DIC/sepsis indication, but they carried the idea too far and killed off whatever modest sales might have occurred in the HD indication.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today